Interleukin-4 and 13 concentrations in infants at risk to develop Bronchopulmonary Dysplasia

BMC Pediatrics

Table 1 Clinical characteristics of Study Subjects

Characteristic	BPD n = 19	no BPD n = 17	p value
Birth weight (grams)	739 ± 27	1052 ± 42	<0.001
Gestation (weeks)	25.3 ± 0.2	27.8 ± 0.5	<0.001
Surfactant therapy	17 (89)	13 (76)	0.296
Ureaplasma isolated	7 (37)	1 (6)	0.026
Mycoplasma isolated	5 (26)	1 (6)	0.100
Chorioamnionitis	1/9 (11)	4/15 (27)	0.430
Antenatal Steroids	9 (53)	10 (53)	0.999
PDA	9 (47)	4 (24)	0.137
Indomethacin^a	17 (89)	10 (59)	0.034
Days MV^b	42 ± 13	7 ± 2	<0.001
Days oxygen^b	64 ± 12	11 ± 2	<0.001
Days hospital^b	104 ± 12	69 ± 6	0.009
MV > 28 days	9 (47)	0	<0.01
Pulmonary hemorrhage	6 (32)	0	0.011
Supplemental O₂ at 36 weeks PCA	3 (16)	0	0.061
Postnatal steroids	16 (84)	7 (41)	0.005
Age steroids started (days)	8 ± 2	9 ± 2	0.758
IVH	6 (32)	5 (29)	0.888
PVL	3 (16)	1 (6)	0.316

PDA-Patent ductus arteriosus; MV-mechanical ventilation, IVH-Intraventricular hemorrhage; PVL-Periventricular leukomalacia; PCA-Postconceptional age. ^aIndomethacin was used prophylactically in most infants. Indomethacin was used to close a clinically significant PDA in 2 control and 7 BPD infants. ^bWilcox Rank Sum test was used because data was not normally distributed. Data are presented as Mean ± SEM or as numbers (percentages)

ISSN: 1471-2431